To hear about similar clinical trials, please enter your email below

Trial Title: Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT ID: NCT06317649

Condition: Acute Myeloid Leukemia

Conditions: Official terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Azacitidine
Venetoclax
Gilteritinib

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Azacitidine
Description: Given IV or SC
Arm group label: Regimen 1 (azacitidine, venetoclax)
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Other name: 5 AZC

Other name: 5-AC

Other name: 5-Azacitidine

Other name: 5-Azacytidine

Other name: 5-AZC

Other name: Azacytidine

Other name: Azacytidine, 5-

Other name: Ladakamycin

Other name: Mylosar

Other name: U-18496

Other name: Vidaza

Intervention type: Procedure
Intervention name: Biospecimen Collection
Description: Undergo blood sample collection
Arm group label: Regimen 1 (azacitidine, venetoclax)
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Other name: Biological Sample Collection

Other name: Biospecimen Collected

Other name: Specimen Collection

Intervention type: Procedure
Intervention name: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Arm group label: Regimen 1 (azacitidine, venetoclax)
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Intervention type: Procedure
Intervention name: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Arm group label: Regimen 1 (azacitidine, venetoclax)
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Other name: Biopsy of Bone Marrow

Other name: Biopsy, Bone Marrow

Intervention type: Drug
Intervention name: Gilteritinib
Description: Given PO
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Other name: ASP 2215

Other name: ASP-2215

Other name: ASP2215

Intervention type: Drug
Intervention name: Venetoclax
Description: Given PO
Arm group label: Regimen 1 (azacitidine, venetoclax)
Arm group label: Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label: Regimen 3 (azacitidine, venetoclax, gilteritinib)

Other name: ABT 199

Other name: ABT-0199

Other name: ABT-199

Other name: ABT199

Other name: GDC 0199

Other name: GDC-0199

Other name: GDC0199

Other name: RG7601

Other name: Venclexta

Other name: Venclyxto

Summary: This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Detailed description: PRIMARY OBJECTIVE: I. To compare the achievement rate of measured residual disease negative (MRDneg) complete remission (CR) of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy. SECONDARY OBJECTIVES: I. To compare the achievement rate of MRDneg CR/complete remission with incomplete count recovery (CRi)/complete remission with partial hematologic recovery (CRh) of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy. II. To determine the safety and tolerability of the combination of gilteritinib, azacitidine, and venetoclax, if both of the triplet regimens show superiority to the azacitidine plus venetoclax regimen. III. To determine the optimal sequence and duration of gilteritinib, when added to azacitidine and venetoclax if both of the triplet regimens show superiority to the azacitidine plus venetoclax regimen. IV. To estimate the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and complete remission with partial hematologic recovery (CRh), morphologic leukemia-free state (MLFS), event-free survival (EFS), and overall survival (OS) of the combination of gilteritinib, azacitidine, and venetoclax versus azacitidine and venetoclax alone. EXPLORATORY OBJECTIVES: I. To establish the degree reduction in FLT3- internal tandem duplication (ITD) mutation burden after 2 and 4 cycles of therapy using a highly sensitive next-generation sequencing (NGS) MRD assay and compare the median reduction in the investigational regimens among patients with CR/CRi/CRh to that of control regimen. II. To determine if the degree of FLT3 ITD reduction is associated with the duration of remission. III. To monitor which mutations are present at the time of relapse. IV. To monitor which co-mutations at presentation are associated with lack of response to these regimens. V. To determine if the FLT3 AR /variant allele frequency (VAF) is associated with response to the regimens. OUTLINE: Patients are randomized to 1 of 3 regimens. REGIMEN 1: INDUCTION: Patients receive azacitidine intravenously (IV) or subcutaneously (SC) on days 1-7 of each cycle and venetoclax orally (PO) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. REGIMEN 2: INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. REGIMEN 3: INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. After completion of study treatment, patients are followed up every 3 months if patient is < 2 years from first registration, and every 6 months if patient is 2-5 years from first registration. All patients, including those who discontinue protocol therapy early, are followed for response until progression, even if non-protocol therapy is initiated, and for survival for 10 years from the date of randomization.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patient must be ≥ 60 years of age or adults ˂ 60 who in the opinion of the treating physician are better served by azanucleoside-based therapy rather than intensive, cytarabine-based induction based on clinical status (i.e., performance status, age > 75 years), organ dysfunction, or disease biology - Patient must have a morphologically confirmed diagnosis of AML according to the World Health Organization (WHO) 2016 classification excluding acute promyelocytic leukemia (APL) with PML-RARA, AML with RUNX1-RUNX1T1, or AML with CBFB-MYH11 - Patient must have no prior therapy for AML with the exception of hydroxyurea and all-trans retinoic acid (ATRA), or leukapheresis. Patients with cytarabine-based emergency therapy prior to the start of therapy on this trial are eligible - Patient must have no prior therapy with hypomethylating agents or FLT3 inhibitors - Patient must have the FLT3-ITD or D835 mutation based on MyeloMATCH Master Screening and Reassessment Protocol (MSRP) - Patient must be assigned to this protocol by the myeloMATCH MSRP - Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. - All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. - A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Patient of childbearing potential and/or sexually active patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 30 days after the last dose of venetoclax for all patients and for 6 months after the last dose of gilteritinib for patients of childbearing potential and for 4 months after the last dose of gilteritinib for male patients with partners of childbearing potential. Patient must not breastfeed during treatment and for 2 months after treatment ends - Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible - Total bilirubin 2X ≤ institutional upper limit of normal (ULN) (unless thought to be elevated due to disease involvement or Gilbert's syndrome) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN - Either measured or estimated by Cockcroft-Gault equation - Creatinine clearance of ≥ 30 mL/min/1.73m^2 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration/randomization are eligible for this trial - Patients must not have a baseline corrected QT interval ≥ 480 msec using Fredericia correction (QTcF). NOTE: Since older patients are at risk for prolonged QTc and many will require supportive care with agents that affect the QTc, an ECG is recommended if clinically indicated. If the QTc is prolonged, they should be treated on tier advancement process (TAP) instead of EA02 - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patient must not have the medical necessity for ongoing treatment with a strong CYP3A4 inducing drug - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - Patients must not have an active or uncontrolled infection

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Yale University

Address:
City: New Haven
Zip: 06520
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 203-785-5702
Email: canceranswers@yale.edu

Investigator:
Last name: Rory M. Shallis
Email: Principal Investigator

Facility:
Name: Veterans Affairs Connecticut Healthcare System-West Haven Campus

Address:
City: West Haven
Zip: 06516
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 203-937-3421

Phone ext: 2832

Investigator:
Last name: Alexander Pine
Email: Principal Investigator

Facility:
Name: Augusta University Medical Center

Address:
City: Augusta
Zip: 30912
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 706-721-2388
Email: ga_cares@augusta.edu

Investigator:
Last name: Vamsi Kota
Email: Principal Investigator

Facility:
Name: Kootenai Health - Coeur d'Alene

Address:
City: Coeur d'Alene
Zip: 83814
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Kootenai Clinic Cancer Services - Post Falls

Address:
City: Post Falls
Zip: 83854
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Kootenai Clinic Cancer Services - Sandpoint

Address:
City: Sandpoint
Zip: 83864
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Northwestern University

Address:
City: Chicago
Zip: 60611
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1301
Email: cancer@northwestern.edu

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Carle at The Riverfront

Address:
City: Danville
Zip: 61832
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@Carle.com

Investigator:
Last name: Suparna Mantha
Email: Principal Investigator

Facility:
Name: Cancer Care Specialists of Illinois - Decatur

Address:
City: Decatur
Zip: 62526
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Decatur Memorial Hospital

Address:
City: Decatur
Zip: 62526
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Kishwaukee

Address:
City: DeKalb
Zip: 60115
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Carle Physician Group-Effingham

Address:
City: Effingham
Zip: 62401
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Suparna Mantha
Email: Principal Investigator

Facility:
Name: Crossroads Cancer Center

Address:
City: Effingham
Zip: 62401
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-876-4762
Email: morganthaler.jodi@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Delnor

Address:
City: Geneva
Zip: 60134
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Glenview Outpatient Center

Address:
City: Glenview
Zip: 60026
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1102

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Grayslake Outpatient Center

Address:
City: Grayslake
Zip: 60030
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 312-695-1102

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Lake Forest Hospital

Address:
City: Lake Forest
Zip: 60045
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: cancertrials@northwestern.edu

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Carle Physician Group-Mattoon/Charleston

Address:
City: Mattoon
Zip: 61938
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Suparna Mantha
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Orland Park

Address:
City: Orland Park
Zip: 60462
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: nctnprogram_rhlccc@northwestern.edu

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: Memorial Hospital East

Address:
City: Shiloh
Zip: 62269
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 314-747-9912
Email: dschwab@wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Southern Illinois University School of Medicine

Address:
City: Springfield
Zip: 62702
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-545-7929

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Springfield Clinic

Address:
City: Springfield
Zip: 62702
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-444-7541

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Springfield Memorial Hospital

Address:
City: Springfield
Zip: 62781
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 217-528-7541
Email: pallante.beth@mhsil.com

Investigator:
Last name: Bryan A. Faller
Email: Principal Investigator

Facility:
Name: Carle Cancer Center

Address:
City: Urbana
Zip: 61801
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-446-5532
Email: Research@carle.com

Investigator:
Last name: Suparna Mantha
Email: Principal Investigator

Facility:
Name: Northwestern Medicine Cancer Center Warrenville

Address:
City: Warrenville
Zip: 60555
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 630-352-5360
Email: Donald.Smith3@nm.org

Investigator:
Last name: Jessica K. Altman
Email: Principal Investigator

Facility:
Name: University of Kansas Clinical Research Center

Address:
City: Fairway
Zip: 66205
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 913-588-3671
Email: KUCC_Navigation@kumc.edu

Investigator:
Last name: Jesus Gonzalez Lugo
Email: Principal Investigator

Facility:
Name: University of Kansas Cancer Center

Address:
City: Kansas City
Zip: 66160
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 913-588-3671
Email: KUCC_Navigation@kumc.edu

Investigator:
Last name: Jesus Gonzalez Lugo
Email: Principal Investigator

Facility:
Name: University of Kansas Hospital-Indian Creek Campus

Address:
City: Overland Park
Zip: 66211
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 913-588-3671
Email: KUCC_Navigation@kumc.edu

Investigator:
Last name: Jesus Gonzalez Lugo
Email: Principal Investigator

Facility:
Name: University of Kansas Hospital-Westwood Cancer Center

Address:
City: Westwood
Zip: 66205
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 913-588-3671
Email: KUCC_Navigation@kumc.edu

Investigator:
Last name: Jesus Gonzalez Lugo
Email: Principal Investigator

Facility:
Name: The James Graham Brown Cancer Center at University of Louisville

Address:
City: Louisville
Zip: 40202
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 502-562-3429

Investigator:
Last name: Mohamed M. Hegazi
Email: Principal Investigator

Facility:
Name: UofL Health Medical Center Northeast

Address:
City: Louisville
Zip: 40245
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 502-852-2755
Email: ctoinfo@louisville.edu

Investigator:
Last name: Mohamed M. Hegazi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Brighton

Address:
City: Brighton
Zip: 48114
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Canton

Address:
City: Canton
Zip: 48188
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Address:
City: Chelsea
Zip: 48118
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Genesee Cancer and Blood Disease Treatment Center

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Genesee Hematology Oncology PC

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Genesys Hurley Cancer Institute

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Hurley Medical Center

Address:
City: Flint
Zip: 48503
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 810-762-8038
Email: wstrong@ghci.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health Saint Mary Mercy Livonia Hospital

Address:
City: Livonia
Zip: 48154
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Address:
City: Ypsilanti
Zip: 48197
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 734-712-7251
Email: MCRCwebsitecontactform@stjoeshealth.org

Investigator:
Last name: Tareq Al baghdadi
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at West County Hospital

Address:
City: Creve Coeur
Zip: 63141
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Washington University School of Medicine

Address:
City: Saint Louis
Zip: 63110
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center-South County

Address:
City: Saint Louis
Zip: 63129
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at Christian Hospital

Address:
City: Saint Louis
Zip: 63136
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Siteman Cancer Center at Saint Peters Hospital

Address:
City: Saint Peters
Zip: 63376
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-600-3606
Email: info@siteman.wustl.edu

Investigator:
Last name: Ramzi Abboud
Email: Principal Investigator

Facility:
Name: Billings Clinic Cancer Center

Address:
City: Billings
Zip: 59101
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 800-996-2663
Email: research@billingsclinic.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Bozeman Health Deaconess Hospital

Address:
City: Bozeman
Zip: 59715
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Benefis Sletten Cancer Institute

Address:
City: Great Falls
Zip: 59405
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Logan Health Medical Center

Address:
City: Kalispell
Zip: 59901
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: Community Medical Center

Address:
City: Missoula
Zip: 59804
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 406-969-6060
Email: mccinfo@mtcancer.org

Investigator:
Last name: John M. Schallenkamp
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Seven Hills

Address:
City: Henderson
Zip: 89052
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Charleston

Address:
City: Las Vegas
Zip: 89102
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: OptumCare Cancer Care at Fort Apache

Address:
City: Las Vegas
Zip: 89148
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 702-384-0013
Email: research@sncrf.org

Investigator:
Last name: John A. Ellerton
Email: Principal Investigator

Facility:
Name: University of New Mexico Cancer Center

Address:
City: Albuquerque
Zip: 87106
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 505-925-0348
Email: HSC-ClinicalTrialInfo@salud.unm.edu

Investigator:
Last name: Charles Foucar
Email: Principal Investigator

Facility:
Name: State University of New York Upstate Medical University

Address:
City: Syracuse
Zip: 13210
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 315-464-5476

Investigator:
Last name: Teresa C. Gentile
Email: Principal Investigator

Facility:
Name: Duke University Medical Center

Address:
City: Durham
Zip: 27710
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 888-275-3853

Investigator:
Last name: Harry P. Erba
Email: Principal Investigator

Facility:
Name: University of Oklahoma Health Sciences Center

Address:
City: Oklahoma City
Zip: 73104
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 405-271-8777
Email: ou-clinical-trials@ouhsc.edu

Investigator:
Last name: Mohamad Khawandanah
Email: Principal Investigator

Facility:
Name: Providence Newberg Medical Center

Address:
City: Newberg
Zip: 97132
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Providence Willamette Falls Medical Center

Address:
City: Oregon City
Zip: 97045
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Providence Portland Medical Center

Address:
City: Portland
Zip: 97213
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Providence Saint Vincent Medical Center

Address:
City: Portland
Zip: 97225
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 503-215-2614
Email: CanRsrchStudies@providence.org

Investigator:
Last name: Alison K. Conlin
Email: Principal Investigator

Facility:
Name: Reading Hospital

Address:
City: West Reading
Zip: 19611
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 610-988-9323

Investigator:
Last name: Terrence P. Cescon
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Spartanburg

Address:
City: Boiling Springs
Zip: 29316
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Easley

Address:
City: Easley
Zip: 29640
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-522-2066
Email: Kim.Williams3@prismahealth.org

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Butternut

Address:
City: Greenville
Zip: 29605
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Faris

Address:
City: Greenville
Zip: 29605
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Eastside

Address:
City: Greenville
Zip: 29615
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Greer

Address:
City: Greer
Zip: 29650
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Prisma Health Cancer Institute - Seneca

Address:
City: Seneca
Zip: 29672
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 864-241-6251

Investigator:
Last name: Suzanne R. Fanning
Email: Principal Investigator

Facility:
Name: Virginia Commonwealth University/Massey Cancer Center

Address:
City: Richmond
Zip: 23298
Country: United States

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: CTOclinops@vcu.edu

Investigator:
Last name: Keri R. Maher
Email: Principal Investigator

Facility:
Name: Centro Comprensivo de Cancer de UPR

Address:
City: San Juan
Zip: 00927
Country: Puerto Rico

Status: Recruiting

Contact:
Last name: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu

Investigator:
Last name: Luis J. Santos Reyes
Email: Principal Investigator

Facility:
Name: San Juan City Hospital

Address:
City: San Juan
Zip: 00936
Country: Puerto Rico

Status: Recruiting

Contact:
Last name: Site Public Contact

Phone: 787-763-1296

Investigator:
Last name: Luis J. Santos Reyes
Email: Principal Investigator

Start date: September 27, 2024

Completion date: October 31, 2025

Lead sponsor:
Agency: National Cancer Institute (NCI)
Agency class: NIH

Source: National Cancer Institute (NCI)

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06317649

Login to your account

Did you forget your password?